Leap Therapeutics Inc
NASDAQ:LPTX
| Market Cap (Intraday) | 98.74M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.59 |
| 50-Day MA | $1.89 |
| 200-Day MA | $2.02 |
Leap Therapeutics Inc Stock, NASDAQ:LPTX
47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts 02141
United States of America
Phone: +1.617.714.0360
Number of Employees: 30
Description
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.